<DOC>
	<DOCNO>NCT01948245</DOCNO>
	<brief_summary>The purpose investigation compare two catheter lock solution ( TaurolockTMHep100 Heparin 100 IE/ml ) , occurence catheter relate blood stream infection , patient intestinal failure central venous access device home parenteral nutrition .</brief_summary>
	<brief_title>Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 Heparin 100 IE/ml .</brief_title>
	<detailed_description>Patients long-term intestinal failure dependent Home Parenteral Nutrition ( HPN ) deliver central venous access device ( CVAD ) , place subcutaneous tunneled catheter ( Broviac ) . Catheter Related Blood Stream Infections ( CRBSI ) frequent complication lead increased morbidity , hospital admission , cost , risk repeat replacement tunnel catheter . The infection often originate contamination catheter hub , growth microorganism inner lumen catheter imbed biofilm . To prevent infection good hygiene guideline use catheter lock solution apply . The primary objective compare two catheter lock solution , TaurolockTMHep100 Heparin 100 IE/ml , occurence CRBSI . The secondary objective compare two device accord efficacy parameter , time infection , cost resource utility , tolerability safety . Patients prior high risk CRBSI include . Patients instill solution CVAD infusion HPN , vary minimum twice per week daily , depend individual HPN programme . Before blinded randomization patient pair accord gender , age prior infection risk . Duration instillation 24 month outcome ( CRBSI ) accure .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Taurolidine</mesh_term>
	<criteria>Patients longterm intestinal failure receive PS least 2 time /week subcutaneously tunnel singlelumen CVC ( Hickman/Broviac ) least one year . Estimated life expectancy ≥1 year Male female patient age 18 80 year Patient fully able understand nature propose intervention give write informed consent enter trial . Patients : expect comply trial plan ( e.g . substance abuse , mental condition ) significant cardiovascular disease unstable angina , recent acute myocardial infarction recent cerebral vascular accident ( within 6 week ) ; cardiac rhythm investigator judgment may result significant hemodynamic effect know hypersensitivity/allergy TauroLockTMHep 100 heparin and/or excipients . pregnant , lactating , nurse abnormal blood coagulation due primary disease due treatment anticoagulant ( warfarin/phenprocoumon , unfractionated heparin , low molecular heparin ) , clinical blood test INR APTT , outside interval give , time inclusion . Patients unfractionated Heparin 100 IE/ml use catheter lock , need APTT test enrollment . Patients treat LowMolecular Heparin , need control INR , thrombocytes plasmaantifactor Xa , If patient increase bleeding risk judge disease clinical blood test , patient can´t include trial . INR 0.93.0 ( warfarin/ phenprocoumon ) APTT need range 25100 second ( Unfractionated Heparin treatment ) Plasmaantifactor Xa ( outside recommend interval ( pro.medicin.dk ) , dependent administration form number daily administration ) . Thrombocytes 100 600 x109/L Patients new catheterrelated thrombosis last 3 month prior inclusion . receive investigational drug within 30 day trial entry receive TauroLockTMHep 100 solution previously antibiotic coat , silver impregnate antimicrobial cuff catheter compromise skin integrity , include infection insertion site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Catheter Related Blood Stream Infection</keyword>
	<keyword>Long-term intestinal Failure</keyword>
	<keyword>Taurolidine</keyword>
	<keyword>Catheter lock solution</keyword>
	<keyword>Antimicrobial agent</keyword>
	<keyword>Home Parenteral Nutrition</keyword>
	<keyword>Anti-infective agent</keyword>
</DOC>